Carl Zeiss Meditec AG

  • WKN: 531370
  • ISIN: DE0005313704
  • Land: Deutschland

Nachricht vom 11.12.2020 | 07:00

Carl Zeiss Meditec reports decline in revenue due to COVID-19 pandemic

DGAP-News: Carl Zeiss Meditec AG / Key word(s): Annual Results
11.12.2020 / 07:00
The issuer is solely responsible for the content of this announcement.

Carl Zeiss Meditec reports decline in revenue due to COVID-19 pandemic
Recurring Revenue stable overall

JENA, 11 December 2020

Carl Zeiss Meditec generated revenue of €1,335.5m in fiscal year 2019/20 (prior year: €1,459.3m), a decline of -8.5% (adjusted for currency effects: -8.7%) year on year. Earnings before interest and taxes (EBIT) decreased to €177.6m (prior year: €264.7m). The EBIT margin was 13.3% (prior year: 18.1%).

"Fiscal year 2019/20 was entirely dominated by the COVID-19 pandemic," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. "Our top priority was the close cooperation with our customers and protecting our employees. We responded quickly to the short-term decline in demand, secured our production and delivery capacity and adjusted costs. A stable overall surgical consumables business also helped to limit the decline in revenue and profit."

Both strategic business units report decline in revenue

Revenue in the Ophthalmic Devices strategic business unit (SBU) decreased by -7.3% in fiscal year 2019/20 (adjusted for currency effects: -7.5%), to €990.6m (prior year: €1,068.6m). Revenue in the Microsurgery SBU decreased by -11.7% (adjusted for currency effects: -12.1%), to €344.8m (prior year: €390.7m). Recurring revenue from consumables, implants and service accounted for a 38.8% share of revenue - a new high after 33.9% in the prior year.

Stable performance in APAC[1] region - significant declines in EMEA[2] and Americas

Revenue in the EMEA region decreased by -13.1% (adjusted for currency effects: -12.7%), to €362.4m (prior year: €417.1m). Declines were recorded particularly in the markets worst affected by the COVID-19 pandemic in Western Europe, the UK, Turkey and the Middle East region. There was a perceptible recovery in Germany toward the end of the reporting period.

The Americas region recorded a revenue decline of -13.2% (adjusted for currency effects:
-13.8%), to €384.0m (prior year: €442.5m). Revenue decreased significantly in the USA and Brazil in particular, after both had achieved growth in the first six months of the fiscal year.

With revenue of €589.0m, the APAC region almost reached the prior-year figure of €599.7m
(-1.8%; adjusted for currency effects: -2.3%), bolstered by a robust recovery in China and South Korea in the second half of the year. The markets of Japan, India and Southeast Asia, on the other hand, showed a decline.

Operating result below prior year

The operating result (earnings before interest and taxes: EBIT) decreased to €177.6m in fiscal year 2019/20 (prior year: €264.7m). The EBIT margin decreased to 13.3% (prior year: 18.1%). Adjusted for special effects, this amounted to 13.8% (prior year: 18.5%). Earnings per share fell to €1.37 (prior year: €1.79).

Carl Zeiss Meditec generally expects to see a recovery of the markets in fiscal year 2020/21 and thus a return to renewed growth in revenue and EBIT. In light of the current COVID-19 infection rates in Europe and North America, however, it cannot be ruled out that the pandemic may cause further strain at the beginning of the new fiscal year. The Company predicts that the first few months of the new fiscal year 2020/21 will lag behind the corresponding year-ago figures for revenue and EBIT.

Revenue by strategic business unit

All figures in €m    12 months
  12 months
  Change from
prior year
Change from prior year
   (adjusted for currency effects)
Ophthalmic Devices 990.6 1,068.6 -7.3% -7.5%
Microsurgery 344.8 390.7 -11.7% -12.1%
Consolidated 1,335.5 1,459.3 -8.5% -8.7%


Revenue by region

All figures in €m         12 Months
  12 months
  Change from
prior year
Change from prior year
         (adjusted for currency effects)
EMEA 362.4 417.1 -13.1% -12.7%
Americas 384.0 442.5 -13.2% -13.8%
APAC 589.0 599.7 -1.8% -2.3%
Consolidated 1,335.5 1,459.3 -8.5% -8.7%

Additional information regarding this publication and the analyst conference call on FY 2019/20 results are available at


Contact for investors and press

Sebastian Frericks
Director Investor Relations, Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-116

[1] Asia/Pacific
[2] Europe, Middle East, Africa

11.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this


International School Augsburg (ISA) – erste Schule in Deutschland geht an die Börse

Die International School Augsburg – ISA- gemeinnützige AG geht als erste Schule in Deutschland an die Börse und macht damit erstmals das Thema „Bildung“ unter ESG-Kriterien investierbar. Mit dem geplanten Emissionserlös soll ein Campus-Neubau finanziert werden, um die hohe Nachfrage bedienen zu können. In unserer Researchstudie haben wir die hohe Bedeutung der ISA für den regionalen Wirtschaftsstandort, eine hohe Stabilität der Geschäftsentwicklung sowie hohe Sicherheiten durch vorhandene Sachwerte ermittelt. Das Rating lautet KAUFEN.

Aktueller Webcast

HelloFresh SE

Publication of the Annual Report & Earnings Call

02. März 2021

Aktuelle Research-Studie

2G Energy AG

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Hinzufügen

01. März 2021